Articles tagged with Myeloid Leukemia
A study published in Leukemia & Lymphoma reveals that IDH mutations drive the production of 2-hydroxyglutarate, leading to abnormal gene regulation and increased risk of relapse. Researchers believe targeting IDH mutations may hold promise for treating AML.
Researchers identify a causal link between the oncometabolite metabolite2-hydroxyglutarate and the onset of acute myeloid leukemia. The study demonstrates how a metabolite can cause cancer, setting the stage for developing inhibitors to block the mutation.
A novel family of experimental agents targeting the transport protein CRM1 may offer a new treatment for acute leukemia. The agents, called KPT-SINEs, have been shown to inhibit leukemia-cell proliferation, arrest cell division, and induce cell death and differentiation in animal models.
Researchers have discovered that activating mutations in the FLT3 gene play a crucial role in acute myeloid leukemia, making it an attractive target for new treatments. The study identifies drug-resistant mutations in FLT3 and suggests that therapies involving combinations of multiple drugs could suppress these mutated forms.
Researchers use groundbreaking gene sequencing technology to rapidly detect FLT3 mutations in AML patients who have relapsed on therapy. This discovery may help develop new therapies to treat AML, a type of leukemia characterized by rapid white blood cell growth.
Scientists have identified PRC2, a chromatin regulator, as a promising therapeutic target in acute myeloid leukemia. Blocking PRC2 halts uncontrolled proliferation and reactivates anti-tumor pathways, offering a potential new treatment option.
Researchers found that certain genetic mutations in acute myeloid leukemia patients predicted improved outcomes when treated with high-dose induction chemotherapy. Mutational profiling could help identify distinct subgroups of patients who may benefit from dose-intensified therapy.
Despite significant progress in treating chronic myeloid leukemia, a cure remains elusive for all patients. Research and adherence to treatments are crucial to advancing the field.
A study published in Leukemia identifies a molecular braking process that acute myeloid leukemia (AML) cells use to evade chemotherapy, allowing them to survive treatment. When this brake is removed, AML cells die, providing hope for improved survival rates for patients with the disease.
A new study has discovered that medications targeting the protein Mcl-1 can rapidly kill aggressive AML cells without harming non-cancerous blood cells. This finding provides hope for improved treatment options and potentially better patient outcomes for AML patients.
Researchers identified a high-risk subgroup among older AML patients with mutated ASXL1 gene, showing significantly shorter survival and lower complete remission rates. The study's findings could lead to more effective targeted therapies for these patients.
A study found that half of tumors from T-cell acute lymphoblastic leukemia (T-ALL) patients expressed genes normally found in stem cells and acute myeloid leukemia (AML) tumors. Additionally, many of these AML-like T-ALL tumors contained specific mutations associated with cancer progression.
A new study assesses the effectiveness of bedside geriatric assessments in identifying vulnerable older adults with acute myelogenous leukemia (AML) who can benefit from aggressive treatment. The assessment tool evaluated cognitive function, psychological state, physical function, and co-morbid disease to provide more individualized tr...
Researchers found a genetic defect in the GATA2 gene that predisposes people to acute myeloid leukemia and myelodysplasia. The mutation affects the production of healthy white blood cells, increasing the risk of severe infections.
Researchers at Cold Spring Harbor Laboratory identify Brd4 as a novel drug target for acute myeloid leukemia, an aggressive blood cancer. The new therapeutic agent, JQ1, shows remarkable anti-leukemia activity and minimal toxicity to non-cancerous cells.
Researchers reveal that MLL-AF9 hijacks Myb to enforce aberrant self-renewal in leukemia cells. Inhibiting Myb results in rapid and complete eradication of cancer, validating a new approach for targeting oncogene addiction in vivo.
Researchers at Wake Forest Baptist Medical Center found a specific mutation in the FLT3 receptor makes cells resistant to standard chemotherapy treatment for acute myeloid leukemia (AML). The study suggests a need for personalized approaches in treatment and may lead to new therapeutic research.
A pilot project aims to improve the accuracy of acute myeloid leukemia (AML) diagnoses in Mexico by standardizing cytogenetic testing. Four Mexican laboratories will participate in the project, which includes a two-year program with oversight from ASH, AMEH, and NCI experts.
Researchers found that higher activity of certain LSC genes was associated with worse overall, event-free and relapse-free survival in acute myeloid leukemia patients. The study defined a signature of enriched AML-initiating cells linked to clinical outcomes.
Onconova Therapeutics presents updated clinical trial results for Estybon (ON 01910.Na) in patients with myelodysplastic syndromes, showing increases in overall survival and bone marrow blast responses. Additionally, ON 013105, a Cyclin D1 inhibitor, demonstrates efficacy in nonclinical models of mantle cell lymphoma.
Researchers found a common genetic alteration in AML patients who died quickly from the disease. DNMT3A mutations were associated with poor survival rates, and patients with these mutations may benefit from aggressive treatment such as bone marrow transplantation.
Researchers discovered a key mutation in the DNA methyltransferase 3A gene that affects AML treatment prognosis, leading to significantly shorter survival times for patients with the mutation. The study's findings suggest that treating patients with this mutation aggressively may improve their outcomes.
For nearly three-quarters of elderly patients, intensive chemotherapy is associated with poor prognosis and low median survival time. Researchers identified several predictive factors for mortality rate, including age over 80, genetic abnormalities, and kidney function impairment.
Researchers identified Musashi 2 as a predictive marker for prognosis in AML and CML patients. High levels of Musashi 2 associated with increased cell proliferation, decreased maturation, and aggressive cancer behavior.
Scientists found that p53 loss enables aberrant self-renewal of myeloid precursors, leading to acute myeloid leukemia. In experiments with living mice, the team demonstrated that a combination of p53 and Kras mutations confers resistance to chemotherapy and promotes aggressive AML.
Researchers identify GRP78 as key factor in mucormycosis pathogenesis, providing new avenue for therapeutics development. PET probes detect distinct immune cell populations, suggesting wider use for immune modulating therapies.
Dr. James Bogenberger has been awarded a 3-year fellowship to research acute myeloid leukemia at TGen, with the goal of identifying therapeutic targets that sensitize AML to epigenetic therapies. The fellowship project aims to translate state-of-the-art biomedical research into novel targeted therapy approaches for leukemia patients.
The study found a strong association between the Human Development Index and rates of stem cell transplantation for acute myeloid leukemia patients. Countries with higher HDI scores had significantly better outcomes, including reduced risk of relapse and improved leukemia-free survival.
Researchers at Ohio State University have discovered a new molecular network that contributes to abnormal KIT protein abundance in acute leukemia cells. Targeting this network with therapeutic drugs may prove more effective than current standard of care.
Researchers at Boston Children's Hospital discovered a possible way to kill off leukemia stem cells and prevent relapse. The study found that targeting the Wnt/beta-catenin pathway can suppress leukemia recurrence by inhibiting beta-catenin, a crucial player in leukemia stem cell development.
Researchers have identified a distinct type of mutation in acute myeloid leukemia patients that could account for half of the remaining cases. The mutations lead to increased production of a molecule called 2HG, which may block the ability of leukemic cells to differentiate into normal blood cells.
A study found that mutations in IDH1 enzyme result in excess production of 2-HG, a metabolite common among cancers including leukemia and brain tumors. Elevated serum levels of 2-HG were detected in approximately 8% of AML patients with these mutations.
A study led by Dr. Tarik Möröy discovered a link between a gene variant and acute myeloid leukemia (AML), a subtype of blood cancer. The GFI136N variant is associated with a 60% higher risk of developing AML, making it a potential biomarker for evaluating prognosis in patients.
A study published in Cancer Cell reveals that epigenetic differences can distinguish patients with acute myeloid leukemia (AML) into subtypes with varying responsiveness to therapy. A set of 15-gene DNA methylation biomarkers was found to be highly predictive of patient survival.
A new study has found that long-duration exposure to formaldehyde used in embalming practices is associated with an increased risk of death from myeloid leukemia. The study, published in the Journal of the National Cancer Institute, also found no associations with other lymphohematopoietic malignancies.
A new study finds that spleen tyrosine kinase (Syk) is a promising therapeutic target for acute myeloid leukemia (AML). The research integrates genetic and proteomic approaches to identify Syk as a potential treatment option.
A comprehensive analysis of childhood acute myeloid leukemia (AML) found only a few genetic mistakes contributing to the disease. The study, published in the Proceedings of the National Academy of Sciences, highlights the need for more detailed examination of AML's complete genome.
Researchers have discovered a protein on the surface of leukemia stem cells that helps them evade macrophage immune cells. Targeting this protein, called CD47, may help increase the body's appetite for killing cancer cells.
Allogeneic stem cell transplantation provides significant overall and relapse-free survival benefits for adult patients with intermediate- and poor-risk acute myeloid leukemia in first complete remission. However, its benefit varies by cytogenetic risk, with no significant advantage for good-risk AML.
Researchers analyzed 24 clinical trials involving over 6,000 AML patients to find that donor stem cell transplant (SCT) in first remission significantly improves survival and reduces disease relapse for those with intermediate-risk disease. This approach is now considered the preferred treatment for this group.
A new study found that boosting miR-29b levels in acute myeloid leukemia cells reverses gene changes, enabling the cells to differentiate and mature. This process could lead to a drop in global DNA methylation and reactivation of tumor suppressor genes, offering a potential treatment for AML.
Researchers developed mouse models of human acute myeloid leukemia (AML) that accurately predict response to chemotherapy and identify key genes promoting resistance or sensitivity. These models provide valuable insights into AML's genetic heterogeneity and may help redesign therapy for maximum benefit.
A new study published in The Lancet Oncology found that azacitidine significantly improves the survival of patients with high-risk forms of myelodysplastic syndromes (MDS). Patients treated with azacitidine had a median overall survival of 24.5 months, compared to 15 months for those receiving conventional care.
Patients with acute myeloid leukemia who received VIDAZA had significantly increased overall survival compared to those treated with conventional care regimens. Approximately half of the AML patients treated with VIDAZA survived at least two years, compared to just 16% of those receiving conventional chemotherapy.
A subset analysis of the AZA-001 trial demonstrated that Vidaza significantly improved overall survival in patients with WHO-defined acute myeloid leukemia (AML) compared to conventional care regimens. The study also showed reduced infections, hospitalizations, and red blood cell transfusions.
Researchers at Ohio State University found that acute myeloid leukemia (AML) patients with mutations in the RAS gene are more likely to be cured when treated with high doses of cytarabine. Testing for RAS mutations may help doctors identify which AML patients should receive this therapy.
Scientists at Cincinnati Children's Hospital Medical Center have discovered that the microenvironment of blood-forming tissues plays a critical role in promoting leukemia progression and determining disease type in mixed lineage leukemias (MLL). The study, which used human-based MLL models in mice, suggests that disrupting the protein ...
Researchers discovered a link between microRNA levels and the risk of relapse in acute myeloid leukemia (AML) patients. The study found that abnormal microRNA patterns were associated with an increased risk of recurrence, providing new insights into possible causes of the disease.
Researchers found a link between low microRNA levels and high gene activity in AML, suggesting new therapeutic targets. The study identified two genes in the Hox family that are over-active in leukemia cells, providing new insights into AML treatment.
New research reveals that timing of IL-7 treatment is crucial for enhancing antiviral immunity. Additionally, studies on cardiac development and wound healing have identified novel genes and mechanisms, offering potential therapeutic targets for chronic viral infections and cutaneous wounds.
Researchers at MD Anderson Cancer Center report a new kidney cancer drug that targets the FLT3-ITD mutation in AML, reducing leukemia cells by 90% in patients. The drug has shown minimal side effects and is being tested in combination with chemotherapy.
Researchers found that the N-Myc gene triggers cancer when paired with growth-promoting protein IL-3 and causes cell suicide without it. The study also shows that immortalized cells overexpressing N-Myc become more aggressive and produce fewer growth-inhibiting proteins.
A new study suggests that acute leukemia patients with a specific genetic mutation may benefit from aggressive therapy to extend their disease-free survival. Researchers found that treating patients with the MLL-PTD mutation with an autologous stem cell transplant significantly reduced early relapses.
A new study by Ohio State University researchers links high ERG gene activity to a more lethal subtype of acute myeloid leukemia (AML). Patients with high ERG expression are almost six times more likely to relapse or die within five years, highlighting the need for more intense therapy.
Researchers found that chronic myeloid leukemia stem cells have a high frequency of BCR-ABL gene mutations, even in the absence of imatinib, which could lead to drug resistance. This genetic instability may contribute to relapses and disease progression.
Most individuals with acute myeloid leukemia (AML) express CDX2, a protein regulating HOX family genes. Reducing CDX2 levels decreases AML cell proliferation, supporting its causal role in leukemogenesis.
A University of Minnesota study found that over 90% of children and young adults who survive five years or longer after diagnosis and treatment for acute myeloid leukemia (AML) are alive 20 years later. Regular health check-ups and monitoring are crucial to prevent late effects of cancer treatment.
Researchers have found that the experimental drug ABT-737 can destroy AML blast, progenitor and stem cells, potentially providing a new way to treat cancer. Combining ABT-737 with another agent may overcome resistance and improve treatment outcomes.
Researchers at the University of Pennsylvania School of Medicine have identified a new protein called Tribbles associated with acute myelogenous leukemia (AML). The study found that Tribbles induces AML by inactivating the C/EBPá protein, providing a potential therapeutic target.
Acute myelogenous leukemia (AML) patients who have multiple active molecular pathways in their blood and bone marrow samples tend to have a poorer prognosis. Targeting just one pathway is unlikely to be effective due to cross-activation, requiring the development of multi-drug therapies.